Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
907 Leser
Artikel bewerten:
(2)

Konica Minolta, Medovate and Mercury Medical Collaborate on Ultrasound-Guided Regional Anesthesia Education at ASRA 2021

Finanznachrichten News

CLEARWATER, FL / ACCESSWIRE / May 11, 2021 / Building on their existing partnership to promote ultrasound-guided regional anesthesia, Konica Minolta Healthcare Americas, Inc. and Medovate, will showcase their combined solution and sponsor educational and training sessions at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 46th Annual Meeting. Mercury Medical, the primary US distributor of Medovate's SAFIRA (SAFer Injection for Regional Anesthesia) will join the two companies in highlighting the importance of using ultrasound-guidance with SAFIRA to improve patient safety and clinical efficiency during regional anesthesia procedures. The meeting will be held May 13-15 in Orlando, Florida.

The combined solution from Konica Minolta and Medovate unites two innovative systems that help promote accuracy and safety while streamlining regional anesthesia procedures. The SONIMAGE® HS2 Compact Ultrasound System features Simple Needle Visualization (SNV®), an advanced algorithm that improves needle visibility and increases accuracy in needle placement, both for in-plane and out-of-plane approaches. SNV also adjusts the sensitivity of needle visualization depending on the type of tissue. At ASRA, attendees can get hands-on experience with the HS2 and SNV in Konica Minolta's booth #209 and with SAFIRA in Medovate's booth #211.

SAFIRA is a novel FDA-cleared device designed to limit injection pressure and automatically stop injection above 20psi to help reduce the risk of nerve injury. In addition to helping limit injectate pressure, SAFIRA also transforms regional anesthesia into a one-physician procedure by allowing a single anesthesiologist to conduct the entire procedure. Previously, an assistant was required to inject the anesthetic solution at the required pressure while the anesthesiologist inserted the needle tip using ultrasound guidance.

Mercury Medical®, Inc. is dedicated to delivering clinically differentiated critical care technology that saves lives throughout the world. For over 55 years clinicians have relied on Mercury Medical as their resource for quickly responding to clinical needs with solutions that improve patient outcomes effectively. The company provides a legacy of innovative products to critical care areas of neonatal, anesthesia, respiratory and EMS markets in more than 58 countries.

At ASRA's 2021 meeting, Medovate is supporting an abstract presentation and poster, "Evaluation of a New Regional Anaesthesia Pump Designed to Help Prevent Nerve Injury," discussing the results of a clinical evaluation involving 34 patients. Additionally, Konica Minolta is sponsoring a webinar with Douglas Jaffe, DO, an anesthesiologist with Wake Forest Baptist Health on regional anesthesia. Dr. Jaffe is an expert in ultrasound-guided regional anesthesia procedures and has published and lectured extensively on the topic.

"At Konica Minolta, we are committed to providing educational and training resources to anesthesiologists who want to adopt best practices and utilize advanced technologies that promote safety and efficiency in regional anesthesia procedures," says Eric Sumner, Executive Vice President Ultrasound Sales at Konica Minolta. "Our collaboration with Medovate and Mercury Medical will highlight the clinical value and patient benefits of regional anesthesia, and help more anesthesiologists provide this important service in their practice."

There are numerous patient benefits resulting from the use of regional anesthesia, including better post-operative analgesia, decreased opioid consumption and length of stay, early rehabilitation, fewer anesthesia-related side effects and high patient satisfaction compared to general anesthesia1,2.

Chris Rogers, Sales & Marketing Director at Medovate comments, "Innovation and improving patient care are at the foundation of the development of SAFIRA. We are delighted to demonstrate the SAFIRA device at the upcoming ASRA meeting. Enabling clinicians to get 'hands on' with the SAFIRA device will really help them understand and see for themselves the potential benefits of the technology for improving outcomes. We look forward to supporting our distributor Mercury Medical and working with Konica Minolta at the 46th Annual ASRA Meeting to help anesthesiologists understand the benefits of a combined solution for regional anesthesia using SAFIRA and leading ultrasound technology from Konica Minolta to help improve patient safety and realize potential cost optimization benefits."

John Gargaro, MD, President and CEO at Mercury Medical adds, "We believe SAFIRA along with the SONIMAGE HS2 will revolutionize regional anesthesia across the United States. As a company, Mercury Medical has a rich experience in bringing innovative, clinically differentiated medical devices to market. These ingenious devices will improve patient safety and operating room efficiency simultaneously by putting the entire regional block procedure back where it belongs - in the anesthesiologists' hands. We are excited to work with Medovate and Konica Minolta to provide additional clinical resources to the attendees at the ASRA event and beyond through our clinical resources. The combination of the SONIMAGE HS2 and SAFIRA delivers the innovation in regional anesthesia that will help drive clinical adoption."

  1. Cozowicz C, Poeran J, Zubizarreta N, et al. Trends in the Use of Regional Anesthesia: Neuraxial and Peripheral Nerve Blocks. Regional Anesthesia & Pain Medicine 2016;41:43-49.
  2. Albrecht, E. and Chin, K.J. Advances in regional anaesthesia and acute pain management: a narrative review. Anaesthesia, 2020; 75: e101-e110.

About Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer's needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit www.konicaminolta.com/medicalusa.

About Medovate

Medovate is a UK based medical device company dedicated to the development and commercialisation of innovative medical technologies created within the National Health Service (NHS) and beyond. Medovate identifies and works with high potential medtech innovations, providing the specialist management and technical resources to guide medical technologies through development, clinical trials, regulatory approval, into manufacture and on through to successful market launch. Medovate accelerates medical device innovations to market in order to benefit patient care and healthcare delivery. The company has a strong portfolio relating to specialisms in anaesthesia, airway management, critical care and surgery. For more information, visit www.medovate.co.uk.

For more information about Mercury Medical, please visit www.mercurymed.com

CONTACT:

D. Olson
Mercury Medical
727-573-4980
www.mercurymed.com

SOURCE: Mercury Medical



View source version on accesswire.com:
https://www.accesswire.com/646400/Konica-Minolta-Medovate-and-Mercury-Medical-Collaborate-on-Ultrasound-Guided-Regional-Anesthesia-Education-at-ASRA-2021

© 2021 ACCESSWIRE
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.